Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MMMT
MCID: CRC021
MIFTS: 62

Carcinosarcoma (MMMT)

Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Carcinosarcoma

About this section

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 12 20 54 44 15 70
Mixed Tumor, Mullerian 20 44 70
Malignant Mixed Mesodermal Tumor 12 70
Malignant Mixed Mullerian Tumor 12 20
Mixed Tumor, Mesodermal 44 17
Mmmt 12 20
Mixed Tumor, Not Otherwise Specified 70
Malignant Mixed Müllerian Tumor 73
Mixed Mesodermal Tumor 12
Mesodermal Mixed Tumor 12
Mullerian Mixed Tumor 12
Mixed Müllerian Tumor 73
Mixed Mullerian Tumor 20
Mixed Tumor Mullerian 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4236
UMLS 70 C0007140 C0206627 C1334603 more
Sources

Summaries for Carcinosarcoma

About this section
GARD : 20 A malignant mixed mullerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as mixed tumor, mullerian, is related to ovarian carcinosarcoma and cervical adenosarcoma. An important gene associated with Carcinosarcoma is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cisplatin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and uterus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : 73 A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Sources

Related Diseases for Carcinosarcoma

About this section

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 854)
# Related Disease Score Top Affiliating Genes
1 ovarian carcinosarcoma 33.0 TP53 PIK3CA ERBB2
2 cervical adenosarcoma 31.6 TP53 PGR MME
3 rare tumor 31.5 KIT DES ACTC1
4 uterine carcinosarcoma 31.2 TP53 PTEN PPP2R1A POLE PIK3CA PGR
5 fibrosarcoma 30.8 VIM TP53 KIT DES ACTC1
6 transitional cell carcinoma 30.8 TP53 PTEN KRT7 HRAS ERBB2
7 spindle cell sarcoma 30.7 VIM MUC1 KRT7 KIT DES ACTC1
8 anal squamous cell carcinoma 30.7 TP53 PIK3CA FBXW7
9 botryoid rhabdomyosarcoma 30.7 MB DES ACTC1
10 fibrous histiocytoma 30.6 VIM KIT DES ACTC1
11 adenosarcoma 30.6 VIM TP53 PGR MME MB KIT
12 bizarre leiomyoma 30.6 TP53 PGR ACTC1
13 malignant fibrous histiocytoma 30.6 VIM TP53 MUC1 MB DES ACTC1
14 benign teratoma 30.6 TP53 MUC1 KRT7
15 neuroendocrine carcinoma 30.5 PTEN MUC1 KRT7 KIT
16 pulmonary blastoma 30.5 TP53 KRAS ACTC1
17 clear cell adenocarcinoma 30.5 TP53 PIK3CA KRT7
18 bilateral breast cancer 30.4 TP53 PTEN PIK3CA PGR ERBB2
19 adenoma 30.4 TP53 PIK3CA MUC1 KRT7 KRAS CTNNB1
20 malignant astrocytoma 30.4 VIM TP53 PTEN ERBB2 CTNNB1
21 embryonal sarcoma 30.4 VIM TP53 KIT DES CTNNB1
22 squamous cell papilloma 30.3 TP53 HRAS
23 eccrine porocarcinoma 30.3 VIM MUC1 KRT7
24 large cell neuroendocrine carcinoma 30.3 KRT7 KIT ERBB2
25 adrenal cortical carcinoma 30.3 VIM TP53 PIK3CA MUC1 CTNNB1
26 mucinous cystadenocarcinoma 30.3 VIM MUC1 KRT7 ACTC1
27 leiomyosarcoma 30.2 VIM TP53 S100A1 PGR MUC1 MB
28 liposarcoma 30.2 VIM TP53 PTEN PIK3CA MB DES
29 medulloepithelioma 30.2 VIM MUC1 KRT7 DES
30 papillary serous adenocarcinoma 30.1 TP53 PGR KRT7 KRAS HRAS
31 spiradenoma 30.1 VIM TP53 S100A1 MUC1 KRT7 ACTC1
32 spindle cell thymoma 30.1 MUC1 DES
33 basal cell carcinoma 30.1 TP53 PTEN MME KRT7 KIT CTNNB1
34 ovarian clear cell carcinoma 30.1 TP53 PTEN PPP2R1A PIK3CA KRT7 KRAS
35 malignant spiradenoma 30.1 TP53 PIK3CA PGR KRT7
36 ameloblastoma 30.1 TP53 KRAS CTNNB1
37 myxofibrosarcoma 30.1 TP53 MUC1 KRAS KIT DES
38 cystic teratoma 30.1 TP53 PTEN KRT7 KRAS KIT
39 mature teratoma 30.1 TP53 KRT7 KRAS KIT ERBB2
40 lung benign neoplasm 30.1 TP53 KRT7 KRAS HRAS
41 vulvar intraepithelial neoplasia 30.1 TP53 CTNNB1
42 squamous cell carcinoma 30.1 TP53 PTEN PIK3CA MUC1 KRT7 HRAS
43 mesenchymal cell neoplasm 30.0 TP53 MME KIT
44 pleomorphic adenoma 30.0 VIM TP53 S100A1 MUC1 KRT7 HRAS
45 in situ carcinoma 30.0 TP53 PTEN PIK3CA PGR MUC1 HRAS
46 papillary transitional carcinoma 30.0 TP53 KRT7
47 primary peritoneal carcinoma 30.0 TP53 PGR ERBB2
48 brooke-spiegler syndrome 30.0 VIM TP53 KRT7
49 wilms tumor 1 30.0 VIM TP53 PGR MUC1 MME KRT7
50 breast mucinous carcinoma 30.0 PGR KRT7 ERBB2

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma
Sources

Symptoms & Phenotypes for Carcinosarcoma

About this section

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.3 HRAS KRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 10.3 HRAS KRAS MUC1 PIK3CA
3 Decreased viability GR00055-A-3 10.3 KRAS
4 Decreased viability GR00106-A-0 10.3 KRAS
5 Decreased viability GR00221-A-1 10.3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.3 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.3 HRAS
8 Decreased viability GR00221-A-4 10.3 PIK3CA
9 Decreased viability GR00249-S 10.3 MUC1
10 Decreased viability GR00301-A 10.3 KRAS
11 Decreased viability GR00381-A-1 10.3 KRAS
12 Decreased viability GR00402-S-2 10.3 PIK3CA
13 Decreased cell migration GR00055-A-1 9.5 VIM
14 Decreased cell migration GR00055-A-3 9.5 HRAS PIK3CA
15 Increased cell death in HCT116 cells GR00103-A-0 9.46 CTNNB1 FBXW7 PIK3CA PPP2R1A
16 Reduced mammosphere formation GR00396-S 9.23 DES HRAS KRAS KRT7 POLE PPP2R1A
17 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Carcinosarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
2 cellular MP:0005384 10.45 ACTC1 CTNNB1 DES ERBB2 FBXW7 KIT
3 homeostasis/metabolism MP:0005376 10.43 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
4 behavior/neurological MP:0005386 10.41 CTNNB1 DES ERBB2 HRAS KIT KRAS
5 mortality/aging MP:0010768 10.31 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
6 embryo MP:0005380 10.29 ACTC1 CTNNB1 ERBB2 FBXW7 KIT KRAS
7 integument MP:0010771 10.23 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
8 muscle MP:0005369 10.21 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
9 endocrine/exocrine gland MP:0005379 10.19 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
10 craniofacial MP:0005382 10.14 ACTC1 CTNNB1 ERBB2 FBXW7 HRAS KIT
11 digestive/alimentary MP:0005381 10.13 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
12 neoplasm MP:0002006 10.1 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
13 nervous system MP:0003631 10.03 ACTC1 CTNNB1 ERBB2 FBXW7 HRAS KIT
14 limbs/digits/tail MP:0005371 9.98 CTNNB1 ERBB2 KIT KRAS PGR PTEN
15 normal MP:0002873 9.77 ACTC1 CTNNB1 ERBB2 FBXW7 HRAS KIT
16 no phenotypic analysis MP:0003012 9.7 CTNNB1 HRAS KIT KRAS PGR PIK3CA
17 respiratory system MP:0005388 9.36 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
Sources

Drugs & Therapeutics for Carcinosarcoma

About this section

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Mesna Approved, Investigational Phase 3 3375-50-6 598
4
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
5
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Liposomal doxorubicin Phase 2, Phase 3 31703
10
Isophosphamide mustard Phase 3 100427
11 Alkylating Agents Phase 3
12
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
13
Bevacizumab Approved, Investigational Phase 2 216974-75-3
14
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
15
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
17
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
18
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
19
Olaparib Approved Phase 2 763113-22-0 23725625
20
Iodine Approved, Investigational Phase 2 7553-56-2 807
21
Metformin Approved Phase 2 657-24-9 14219 4091
22
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
23
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
24
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
25
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
26
Gemcitabine Approved Phase 2 95058-81-4 60750
27
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
28
Durvalumab Approved, Investigational Phase 2 1428935-60-7
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
31
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
34
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
35
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
36
Iniparib Investigational Phase 2 160003-66-7
37
Saracatinib Investigational Phase 2 379231-04-6
38
Cediranib Investigational Phase 2 288383-20-0 9933475
39
Entinostat Investigational Phase 1, Phase 2 209783-80-2
40
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
41
Tremelimumab Investigational Phase 2 745013-59-6
42 Angiogenesis Inhibitors Phase 2
43 Epothilones Phase 2
44 Epothilone B Phase 2
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Liver Extracts Phase 2
47
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
48 Fluorodeoxyglucose F18 Phase 1, Phase 2
49 Cola Phase 2
50 Poly(ADP-ribose) Polymerase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
5 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
6 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
7 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
8 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
9 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
10 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
11 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
12 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
13 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
14 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
15 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
16 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
17 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
18 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
19 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
20 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
21 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
22 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
23 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
24 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
25 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
26 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes Recruiting NCT04171700 Phase 2 Rucaparib
27 A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
28 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
30 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
31 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
32 A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion Recruiting NCT03933761 Phase 2 Pamiparib
33 A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2) Recruiting NCT04513665 Phase 2 ZW25
34 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
35 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
36 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
37 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
38 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
39 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Autologous Tumor Infiltrating Lymphocytes LN-145-S1;Cyclophosphamide;Fludarabine
40 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
41 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Recruiting NCT03241745 Phase 2 Nivolumab
42 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma Active, not recruiting NCT03395080 Phase 2 Paclitaxel;300mg DKN-01;600mg DKN-01
43 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Active, not recruiting NCT02993705 Phase 2 Trabectedin
44 A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma Active, not recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
45 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
46 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
47 Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff Not yet recruiting NCT04802876 Phase 2 Spartalizumab
48 A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus. Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
49 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
50 A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Sources

Genetic Tests for Carcinosarcoma

About this section
Sources

Anatomical Context for Carcinosarcoma

About this section

MalaCards organs/tissues related to Carcinosarcoma:

40
Ovary, Cervix, Uterus, Breast, Lung, Thyroid, Prostate
Sources

Publications for Carcinosarcoma

About this section

Articles related to Carcinosarcoma:

(show top 50) (show all 3793)
# Title Authors PMID Year
1
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 61 54
20189232 2010
2
Intraductal carcinosarcoma with a heterologous mesenchymal component originating in intraductal papillary-mucinous carcinoma (IPMC) of the pancreas with both carcinoma and osteosarcoma cells arising from IPMC cells. 61 54
20203229 2010
3
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. 54 61
19200930 2009
4
Carcinosarcoma of the gallbladder producing alpha-fetoprotein and manifesting as leukocytosis with elevated serum granulocyte colony-stimulating factor: report of a case. 54 61
19280285 2009
5
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. 54 61
16648864 2006
6
Carcinosarcoma of the liver producing granulocyte-colony stimulating factor. 61 54
16792552 2006
7
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 61 54
16140564 2006
8
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 61 54
16157366 2006
9
Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. 54 61
15950966 2005
10
Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. 61 54
15863125 2005
11
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 61 54
15901136 2005
12
ERBB-2 gene overexpression and amplification in uterine sarcomas. 54 61
15581967 2004
13
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. 61 54
15223963 2004
14
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. 54 61
12604887 2003
15
Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. 54 61
11180164 2001
16
Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. 54 61
9786352 1998
17
Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. 54 61
9500227 1998
18
Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. 54 61
9313326 1997
19
Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. 54 61
1457347 1992
20
Immunohistochemical study of the histogenesis of esophageal carcinosarcoma. 61 54
1283991 1992
21
Thymic carcinosarcoma associated with a spindle cell thymoma: an immunohistochemical study. 54 61
1398523 1992
22
Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. 54 61
1612579 1992
23
Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 61 54
1672262 1991
24
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. 54 61
2201434 1990
25
An immunohistological comparison of primary lung carcinosarcoma and sarcoma. 54 61
1696005 1990
26
The use of neoadjuvant chemotherapy in advanced endometrial cancer. 61
33644284 2021
27
Cervical malignant mixed mesonephric tumour: A case report with local recurrence after six-years and next-generation sequencing analysis with particular reference to the ataxia telangiectasia mutated gene. 61
33680116 2021
28
Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach). 61
33234261 2021
29
Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. 61
33368243 2021
30
COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. 61
33649798 2021
31
Atypical vessels in hysteroscopy: Usefulness in prediction of malignant diseases in patients treated with tamoxifen. 61
33522085 2021
32
Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. 61
33692852 2021
33
Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. 61
32564423 2021
34
Experience of the pancreas duodenectomy for so-called carcinosarcoma of the common bile duct:a case report and review of literature. 61
33786287 2021
35
FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas. 61
33811207 2021
36
The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma. 61
33481373 2021
37
Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma. 61
33565764 2021
38
SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. 61
33720083 2021
39
First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder. 61
33727576 2021
40
FOXA1 Expression by Immunohistochemistry in Carcinosarcomas of the Endometrium and Ovary/Fallopian Tube. 61
33770058 2021
41
Canine mammary cancer tumour behaviour and patient survival time are associated with collagen fibre characteristics. 61
33707516 2021
42
Pancreatic Carcinosarcoma Clinical Outcome Analysis of the National Cancer Institute Database. 61
33279845 2021
43
Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma. 61
33687154 2021
44
Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma. 61
33785723 2021
45
A case of 18 years disease-free survival after combined pancreatoduodenectomy and hemicolectomy for carcinosarcoma of the transverse colon. 61
33765265 2021
46
Imaging-guided percutaneous radiofrequency ablation of retroperitoneal metastatic disease in uterine carcinosarcoma. 61
33645390 2021
47
Gastric Remnant Carcinosarcoma: Case Report and Review of the Literature. 61
32607961 2021
48
Yolk Sac Tumor Arising in Uterine Carcinosarcoma With Endometrioid and Serous Components: A Case Report With Immunohistochemical Analysis. 61
33770060 2021
49
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study. 61
33722415 2021
50
Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports. 61
33761637 2021
Sources

Variations for Carcinosarcoma

About this section

Cosmic variations for Carcinosarcoma:

9 (show top 50) (show all 1019)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144650860 TP53 cervix,NS,carcinoma,adenocarcinoma c.584A>G p.Y195C 17:7674262-7674262 3
2 COSM144651115 TP53 cervix,NS,carcinoma,adenocarcinoma c.626G>A p.R209Q 17:7674220-7674220 3
3 COSM112253879 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 3
4 COSM87935416 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 3
5 COSM111758336 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 3
6 COSM142838165 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.797G>A p.G266E 17:7673823-7673823 3
7 COSM93303215 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
8 COSM122733941 TP53 cervix,NS,carcinoma,adenocarcinoma c.305A>G p.Y102C 17:7674262-7674262 3
9 COSM112374468 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
10 COSM111879853 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
11 COSM144682712 TP53 cervix,NS,carcinoma,adenocarcinoma c.382C>T p.Q128* 17:7675113-7675113 3
12 COSM122302302 TP53 cervix,NS,carcinoma,adenocarcinoma c.103C>T p.Q35* 17:7675113-7675113 3
13 COSM144116151 TP53 cervix,NS,carcinoma,adenocarcinoma c.644G>T p.G215V 17:7674286-7674286 3
14 COSM144650788 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.614G>A p.G205D 17:7674232-7674232 3
15 COSM143484735 TP53 cervix,NS,carcinoma,adenocarcinoma c.560G>T p.G187V 17:7674286-7674286 3
16 COSM144409660 TP53 cervix,NS,carcinoma,adenocarcinoma c.560G>T p.G187V 17:7674286-7674286 3
17 COSM121910283 TP53 cervix,NS,carcinoma,adenocarcinoma c.103C>T p.Q35* 17:7675113-7675113 3
18 COSM87898709 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 3
19 COSM144186978 TP53 cervix,NS,carcinoma,adenocarcinoma c.200G>T p.G67V 17:7674286-7674286 3
20 COSM144013119 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.698G>A p.G233D 17:7674232-7674232 3
21 COSM122733885 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.335G>A p.G112D 17:7674232-7674232 3
22 COSM145045823 TP53 cervix,NS,carcinoma,adenocarcinoma c.382C>T p.Q128* 17:7675113-7675113 3
23 COSM144310429 TP53 cervix,NS,carcinoma,adenocarcinoma c.625C>T p.R209W 17:7674221-7674221 3
24 COSM144311239 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.680G>A p.G227E 17:7673823-7673823 3
25 COSM93183630 TP53 cervix,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 3
26 COSM144013367 TP53 cervix,NS,carcinoma,adenocarcinoma c.710G>A p.R237Q 17:7674220-7674220 3
27 COSM142560012 TP53 cervix,NS,carcinoma,adenocarcinoma c.584A>G p.Y195C 17:7674262-7674262 3
28 COSM122734399 TP53 cervix,NS,carcinoma,adenocarcinoma c.346C>T p.R116W 17:7674221-7674221 3
29 COSM144334467 TP53 cervix,NS,carcinoma,adenocarcinoma c.382C>T p.Q128* 17:7675113-7675113 3
30 COSM144652452 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.680G>A p.G227E 17:7673823-7673823 3
31 COSM144310011 TP53 cervix,NS,carcinoma,adenocarcinoma c.584A>G p.Y195C 17:7674262-7674262 3
32 COSM142560553 TP53 cervix,NS,carcinoma,adenocarcinoma c.625C>T p.R209W 17:7674221-7674221 3
33 COSM143370668 TP53 cervix,NS,carcinoma,adenocarcinoma c.584A>G p.Y195C 17:7674262-7674262 3
34 COSM142837551 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 3
35 COSM111790424 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 3
36 COSM144087882 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.320G>A p.G107E 17:7673823-7673823 3
37 COSM106054488 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.797G>A p.G266E 17:7673823-7673823 3
38 COSM144778606 TP53 cervix,NS,carcinoma,adenocarcinoma c.560G>T p.G187V 17:7674286-7674286 3
39 COSM142939594 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
40 COSM111758260 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.731G>A p.G244D 17:7674232-7674232 3
41 COSM144111084 TP53 cervix,NS,carcinoma,adenocarcinoma c.22C>T p.Q8* 17:7675113-7675113 3
42 COSM144013676 TP53 cervix,NS,carcinoma,adenocarcinoma c.709C>T p.R237W 17:7674221-7674221 3
43 COSM106084061 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 3
44 COSM143182864 TP53 cervix,NS,carcinoma,adenocarcinoma c.22C>T p.Q8* 17:7675113-7675113 3
45 COSM93183394 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 3
46 COSM122735201 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.401G>A p.G134E 17:7673823-7673823 3
47 COSM112253189 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 3
48 COSM144013181 TP53 cervix,NS,carcinoma,adenocarcinoma c.668A>G p.Y223C 17:7674262-7674262 3
49 COSM144087106 TP53 cervix,NS,carcinoma,adenocarcinoma c.266G>A p.R89Q 17:7674220-7674220 3
50 COSM106172737 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
Sources

Expression for Carcinosarcoma

About this section
Search GEO for disease gene expression data for Carcinosarcoma.
Sources

Pathways for Carcinosarcoma

About this section

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
2
ERK Signaling 63
Show member pathways
 13.85 VIM TP53 PTEN PPP2R1A MUC1 KRAS
3
HIV Life Cycle 65
Show member pathways
 13.76 PPP2R1A PIK3CA MUC1 KRAS KIT HRAS
4
Developmental Biology 65
Show member pathways
 13.54 PPP2R1A PIK3CA KRT7 KRAS KIT HRAS
5
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.5 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 VIM TP53 PPP2R1A PIK3CA MUC1 KRAS
7
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.31 VIM PPP2R1A KRAS KIT HRAS ERBB2
8
PI3K/AKT activation 65
Show member pathways
 13.16 TP53 PTEN PPP2R1A PIK3CA KIT ERBB2
9
Focal Adhesion 36 1
Show member pathways
 12.94 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
10
PI3K-Akt signaling pathway 36
Show member pathways
 12.89 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
11
Endometrial cancer 36
Show member pathways
 12.84 TP53 PTEN PIK3CA KRAS HRAS ERBB2
12
MAPK signaling pathway 36 1
12.8 TP53 KRAS KIT HRAS ERBB2
13
Pathways in cancer 36
12.8 TP53 PTEN PIK3CA KRAS KIT HRAS
14
Ras signaling pathway 36
Show member pathways
 12.77 PIK3CA KRAS KIT HRAS CTNNB1
15
Development HGF signaling pathway 23
Show member pathways
 12.74 TP53 PTEN PIK3CA KRAS HRAS ERBB2
16
Glioma 36
Show member pathways
 12.73 TP53 PTEN PIK3CA KRAS HRAS ERBB2
17
Immune response IL-23 signaling pathway 23
Show member pathways
 12.65 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
18
T cell receptor signaling pathway 36
Show member pathways
 12.64 VIM PTEN PIK3CA KRAS HRAS
19
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.61 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
20
Gastric cancer 36
Show member pathways
 12.58 TP53 PTEN PIK3CA PGR KRAS KIT
21
Cytoskeletal Signaling 4
12.57 VIM MUC1 KRT7 DES ACTC1
22
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.56 TP53 PTEN PIK3CA KRAS HRAS ERBB2
23
ErbB signaling pathway 36 1
Show member pathways
 12.55 TP53 PTEN PIK3CA KRAS HRAS ERBB2
24
Prolactin Signaling Pathway 1 36
Show member pathways
 12.53 PTEN PIK3CA KRAS HRAS ERBB2
25
Apoptosis Pathway 69
Show member pathways
 12.49 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
26
MicroRNAs in cancer 36
12.49 VIM TP53 PTEN PIK3CA KRAS HRAS
27
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.45 PTEN PIK3CA KRAS HRAS
28
Phospholipase D signaling pathway 36
Show member pathways
 12.44 PIK3CA KRAS KIT HRAS
29
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.44 PIK3CA KRAS HRAS CTNNB1
30
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.44 PIK3CA KRAS KIT HRAS ERBB2 CTNNB1
31
Development IGF-1 receptor signaling 23
Show member pathways
 12.43 TP53 PTEN PIK3CA HRAS
32
Oocyte meiosis 36
Show member pathways
 12.41 PPP2R1A PIK3CA PGR KRAS
33
Human T-cell leukemia virus 1 infection 36
12.4 TP53 PTEN PIK3CA KRAS HRAS
34
VEGF Signaling 66
Show member pathways
 12.37 TP53 PTEN MUC1 KRAS HRAS CTNNB1
35
Signaling by ERBB2 65
Show member pathways
 12.35 PIK3CA KRAS HRAS ERBB2
36
Viral carcinogenesis 36
12.34 TP53 PIK3CA KRAS HRAS
37
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.33 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
38
Signaling by FGFR2 65
Show member pathways
 12.31 PPP2R1A PIK3CA KRAS HRAS
39
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.29 TP53 PTEN PIK3CA KRAS HRAS ERBB2
40
Proteoglycans in cancer 36
12.28 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
41
Development EGFR signaling pathway 23
Show member pathways
 12.26 PIK3CA MUC1 KRAS HRAS ERBB2 CTNNB1
42
EGF/EGFR Signaling Pathway 1
12.23 PTEN KRAS HRAS ERBB2
43
Kit receptor signaling pathway 1
Show member pathways
 12.22 PTEN PIK3CA KIT HRAS
44
Cellular senescence (KEGG) 36
12.22 TP53 PTEN PIK3CA KRAS HRAS
45
mTOR Pathway 69
Show member pathways
 12.21 TP53 PIK3CA KRAS HRAS
46
Development EGFR signaling via small GTPases 23
Show member pathways
 12.2 PTEN PIK3CA KRAS HRAS ERBB2
47
Integrated Breast Cancer Pathway 1
12.19 TP53 PTEN KRAS CTNNB1
48
Longevity regulating pathway 36
Show member pathways
 12.18 TP53 PIK3CA KRAS HRAS
49
Signaling pathways regulating pluripotency of stem cells 36
12.15 PIK3CA KRAS HRAS CTNNB1
50
Estrogen signaling pathway (KEGG) 36
12.13 PIK3CA PGR KRAS HRAS
Sources

GO Terms for Carcinosarcoma

About this section

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 VIM PTEN PPP2R1A POLE PIK3CA MUC1
2 extracellular exosome GO:0070062 9.97 VIM PPP2R1A MUC1 MME MB KRT7
3 cytosol GO:0005829 9.86 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
4 focal adhesion GO:0005925 9.65 VIM MME KRAS CTNNB1 ACTC1
5 cytoplasm GO:0005737 9.58 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
6 fascia adherens GO:0005916 9.4 DES CTNNB1
7 intercalated disc GO:0014704 9.33 PIK3CA DES CTNNB1

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 PTEN KRAS KIT HRAS ERBB2 CTNNB1
2 heart development GO:0007507 9.84 TP53 PTEN ERBB2 CTNNB1
3 negative regulation of gene expression GO:0010629 9.8 TP53 PGR HRAS FBXW7 CTNNB1
4 Ras protein signal transduction GO:0007265 9.7 TP53 KRAS HRAS
5 embryonic organ development GO:0048568 9.65 TP53 POLE CTNNB1
6 muscle filament sliding GO:0030049 9.63 VIM DES ACTC1
7 positive regulation of MAPK cascade GO:0043410 9.62 KIT HRAS ERBB2 CTNNB1
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.61 PTEN PIK3CA ERBB2
9 response to isolation stress GO:0035900 9.51 KRAS HRAS
10 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.49 TP53 MUC1
11 positive regulation of MAP kinase activity GO:0043406 9.46 KRAS KIT HRAS ERBB2
12 vasculature development GO:0001944 9.43 PIK3CA FBXW7 CTNNB1
13 cytokine-mediated signaling pathway GO:0019221 9.43 VIM TP53 PIK3CA MUC1 KRAS KIT
14 positive regulation of gene expression GO:0010628 9.28 VIM TP53 PTEN KRAS KIT HRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.28 VIM TP53 S100A1 PTEN PGR KRAS
Sources

Sources for Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....